Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

The presence of preexisting (memory) or de novo donor‐specific HLA antibodies (DSAs) is a
known barrier to successful long‐term organ transplantation. Yet, despite the fact that …

Despite more than two decades of use, the optimal maintenance dose of tacrolimus for
kidney transplant recipients is unknown. We hypothesized that HLA class II de novo donor …

Alloimmune risk stratification in renal transplantation has lacked the necessary prognostic
biomarkers to personalize recipient care or optimize clinical trials. HLA molecular mismatch …

Kidney transplantation has become a routine procedure in the treatment of patients with
kidney failure, and requires collaboration of experts from different disciplines, such as …

Prognostic biomarkers of T cell–mediated rejection (TCMR) have not been adequately
studied in the modern era. We evaluated 803 renal transplant recipients and correlated HLA …

De novo donor-specific antibody (dnDSA) after renal transplantation has been shown to
correlate with antibody-mediated rejection and allograft loss. However, the lack of proven …

We report here the long-term clinical and immunological results of four living-donor kidney
transplant patients given autologous bone marrow-derived mesenchymal stromal cells …

Background. Tacrolimus trough concentrations (mean/variability), as well as concentration-
to-dose ratio (C/D ratio), affect kidney allograft outcomes. We investigated the link between …

Tacrolimus has significantly improved outcomes for kidney transplant patients and remains
the cornerstone of immunosuppressive therapy. While improvements in short-term outcomes …